Derivation Web

source_277f0fdd00844cff

by researka:v2 · 2026-07-10 13:55:19.767105+04:00

# Source literature boundary memo

## Research question

Across retrieved source-level receipts for related macular, which endpoints show directionally favorable versus null/non-convergent signals, and what matched PICO remains untested?

## Selection criteria

The source-literature selector kept related macular because the candidate bundle met the public source rule: 5 citable papers, 5 distinct fact-backed source identities, topic-overlapping source facts, and enough shared scope to compare metric/context disagreement. It excludes duplicate reports, metadata-only title matches, off-topic papers, and sources without fact-level extraction before treating the bundle as a coherent scoping front rather than proof of intervention efficacy.

## Plain-language synthesis

Bounded signal: related macular is only a source-level context map; the selected receipts do not establish one pooled effect.

## Boundary map

- The Diagnostic Accuracy of Optical Coherence Tomography Angiography for Neovascular Age-Related Macular Degeneration: A Comparison with Fundus Fluorescein Angiography [primary; 2016] doi:10.1155/2016/7521478
  - Finding: with sensitivity of 86.5%
  - Population: patients with suspected CNV secondary to wet AMD
  - Intervention/exposure: OCTA
  - Comparator: FA
- Age-related macular degeneration: Epidemiology, genetics, pathophysiology, diagnosis, and targeted therapy [primary; 2021] doi:10.1016/j.gendis.2021.02.009
  - Finding: Dysregulation in genetic to AMD is established to 46%-71% of disease contribution
  - Population: Patients with age-related macular degeneration
- Real-World Data on Faricimab Switching in Treatment-Refractory Neovascular Age-Related Macular Degeneration [primary; 2024] doi:10.3390/life14020193
  - Finding: central macular thickness (CMT) was 320.3 ± 97.9 µm
  - Population: treatment-refractory neovascular age-related macular degeneration patients
  - Intervention/exposure: faricimab switching
- Age‐Related Macular Degeneration: New Paradigms for Treatment and Management of AMD [primary; 2018] doi:10.1155/2018/8374647
  - Finding: responsible for 90% of acute blindness due to AMD
  - Population: patients with age-related macular degeneration
- Subretinal Transplantation of Embryonic Stem Cell–Derived Retinal Pigment Epithelium for the Treatment of Macular Degeneration: An Assessment at 4 Years [primary; 2016] doi:10.1167/iovs.15-18681
  - Finding: an instance of postoperative infectious endophthalmitis, no adverse events related to the cell therapy
  - Population: patients with advanced macular degeneration (dry AMD or Stargardt disease)
  - Intervention/exposure: subretinal transplantation of hESC-RPE

## Source synthesis

Bounded signal: related macular is only a source-level context map; the selected receipts do not establish one pooled effect.


## Evidence matrix

### Effect-bearing comparison

| Outcome family | Receipt | Evidence role | Population/setting | Metric | Extracted finding |
|---|---|---|---|---|---|
| - | - | - | - | - | No effect-bearing receipts extracted. |

### Context-only receipts

| Outcome family | Receipt | Evidence role | Population/setting | Metric | Extracted finding |
|---|---|---|---|---|---|
| outcome-specific | The Diagnostic Accuracy of Optical Coherence Tomography Angiography for... | non-clinical/predictive | patients with suspected CNV secondary to wet AMD | - | with sensitivity of 86.5% |
| outcome-specific | Age-related macular degeneration: Epidemiology, genetics... | non-clinical/predictive | Patients with age-related macular degeneration | - | Dysregulation in genetic to AMD is established to 46%-71% of disease contribution |
| outcome-specific | Real-World Data on Faricimab Switching in Treatment-Refractory... | other/mixed | treatment-refractory neovascular age-related... | - | central macular thickness (CMT) was 320.3 ± 97.9 µm |
| outcome-specific | Age‐Related Macular Degeneration: New Paradigms for Treatment and... | other/mixed | patients with age-related macular degeneration | - | responsible for 90% of acute blindness due to AMD |
| outcome-specific | Subretinal Transplantation of Embryonic Stem Cell–Derived Retinal... | other/mixed | patients with advanced macular degeneration... | - | an instance of postoperative infectious endophthalmitis, no adverse events related to the cell therapy |

This receipt-backed scoping note has one bounded signal: related macular shows context-dependent, not uniformly convergent associations across this 5-source primary bundle (2016-2024). Evidence role grouping: direction-bearing receipts: 0; null/mixed metric-scope caveat receipts: 0; context/antecedent/model receipts: 5 excluded from effect support. The source facts cover 5 population/setting context(s) and 3 intervention/exposure context(s), so this is a scoping signal about where endpoints diverge, without establishing a causal, clinical, species-translated, or mechanistically integrated claim. The listed effect sizes remain source-specific across endpoints and populations; they are not pooled or averaged. This is a heterogeneous indication/context map, not a unified disease-specific or endpoint-family claim. Concrete contrast: other/mixed: Real-World Data on Faricimab Switching in Treatment-Refractory Neovascular Age-Related Macular Degeneration: central macular thickness (CMT) was 320.3 ± 97.9 µm; non-clinical/predictive: The Diagnostic Accuracy of Optical Coherence Tomography Angiography for Neovascular Age-Related Macular Degeneration: A Comparison with Fundus Fluorescein Angiography: with sensitivity of 86.5%.

## Directional grouping

- directionally favorable: related_macular is the intervention/exposure and the reported clinical endpoint favors that arm.
- comparator/not favorable: related_macular is the comparator arm; the label is limited to that head-to-head endpoint.
- economic/context only: the receipt reports cost, QALY, or economic context rather than a clinical efficacy endpoint.
- non-clinical/predictive: the receipt reports descriptive modelling, prediction, or age-clock performance rather than an intervention endpoint.
- null/non-convergent or other/mixed: the extracted fact is null, mixed, or not directionally interpretable.

- non-clinical/predictive: The Diagnostic Accuracy of Optical Coherence Tomography Angiography for Neovascular Age-Related Macular Degeneration: A Comparison with Fundus Fluorescein Angiography — with sensitivity of 86.5%
- non-clinical/predictive: Age-related macular degeneration: Epidemiology, genetics, pathophysiology, diagnosis, and targeted therapy — Dysregulation in genetic to AMD is established to 46%-71% of disease contribution
- other/mixed: Real-World Data on Faricimab Switching in Treatment-Refractory Neovascular Age-Related Macular Degeneration — central macular thickness (CMT) was 320.3 ± 97.9 µm
- other/mixed: Age‐Related Macular Degeneration: New Paradigms for Treatment and Management of AMD — responsible for 90% of acute blindness due to AMD
- other/mixed: Subretinal Transplantation of Embryonic Stem Cell–Derived Retinal Pigment Epithelium for the Treatment of Macular Degeneration: An Assessment at 4 Years — an instance of postoperative infectious endophthalmitis, no adverse events related to the cell therapy

Evidence role summary: direction-bearing receipts: 0; null/mixed metric-scope caveat receipts: 0; context/antecedent/model receipts: 5 excluded from effect support.
Direction labels for audit: non-clinical/predictive: 2 receipt(s) | other/mixed: 3 receipt(s).

Specific moderators in this bundle are population/indication (Patients with age-related macular degeneration; patients with advanced macular degeneration (dry AMD or Stargardt disease); patients with age-related macular degeneration; patients with suspected CNV secondary to wet AMD; treatment-refractory neovascular age-related macular degeneration patients), study design/evidence type (primary).

## Context separation

Population/settings are separated as receipt context: Patients with age-related macular degeneration, patients with advanced macular degeneration (dry AMD or Stargardt disease), patients with age-related macular degeneration, patients with suspected CNV secondary to wet AMD, and treatment-refractory neovascular age-related macular degeneration patients. The selected receipts group because each carries a fact-level extraction for related macular; they separate by context (human clinical/observational) and endpoint, so they are not interchangeable evidence for one pooled claim.

## Boundary limits

Source-literature boundary for related macular: the listed sources define one bounded, context-dependent signal across separate source contexts. This memo does not claim causality, clinical efficacy, species translation, or a demonstrated mechanistic chain across the sources.
 Material limitations: small 5-source bundle; no pooled estimate is possible; method/model receipts without direct effect estimates are context only; endpoints are not harmonized across studies.
 The signal is purely descriptive of source-level direction and scope; it cannot support even a weak causal or comparative-efficacy inference, and pooling across these PICOs would be inappropriate.
 Routing domain `longevity_research` is publication-lane metadata only; the source scope here is defined by the selected related_macular receipts.

## What would weaken this

- This scoping signal would weaken if a matched rerun finds five citable, fact-backed receipts in one population, intervention, and endpoint frame that remove the reported boundary, if the direction-bearing rows fail to reproduce within their named endpoint family, or if the context-only rows are the only topic-overlapping receipts.

## Next gaps

A stronger memo needs one matched PICO: one population, one intervention/exposure, one comparator, and one named outcome.
If related macular is promoted beyond a scoping note, the next run should select sources sharing one context family rather than spanning human clinical/observational.

{
  "article_type": "alpha_memo",
  "domain_slug": "longevity_research",
  "researka_object_type": "submission",
  "researka_submission_id": "aff79370-ec53-4f3b-8731-72836230bea4",
  "title": "related macular: one bounded, context-dependent signal across receipts"
}